Eric B. Haura

25.0k total citations · 3 hit papers
278 papers, 14.7k citations indexed

About

Eric B. Haura is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Eric B. Haura has authored 278 papers receiving a total of 14.7k indexed citations (citations by other indexed papers that have themselves been cited), including 147 papers in Molecular Biology, 145 papers in Oncology and 126 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Eric B. Haura's work include Lung Cancer Treatments and Mutations (116 papers), Lung Cancer Research Studies (36 papers) and Cancer Genomics and Diagnostics (34 papers). Eric B. Haura is often cited by papers focused on Lung Cancer Treatments and Mutations (116 papers), Lung Cancer Research Studies (36 papers) and Cancer Genomics and Diagnostics (34 papers). Eric B. Haura collaborates with scholars based in United States, South Korea and Italy. Eric B. Haura's co-authors include Lanxi Song, Richard Jove, James Turkson, Domenico Coppola, Gerold Bepler, W. Douglas Cress, Joseph R. Nevins, Katsuyuki Tamai, Faison Nuckolls and Yoichi Taya and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Eric B. Haura

266 papers receiving 14.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability

2000 1.0k citations Eric B. Haura et al. profile →
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

2002 1.0k citations Lanxi Song, Eric B. Haura et al. profile →
Src kinases as therapeutic targets for cancer

2009 569 citations Lanxi Song, Eric B. Haura et al. profile →

Peers

Eric B. Haura

ONCOL

PRM

IMMUN

Timothy A. Yap United States

Phillip A. Dennis United States

Michèle Milella Italy

Kazuto Nishio Japan

Sandrine Faivre France

Robert L. Sutherland Australia

Роберто Пили United States

Elisa Giovannetti Netherlands

Filip Jankú United States

Wilson H. Miller Canada

Timothy A. Yap United States

Eric B. Haura

9.0k ×1.0

8.6k ×1.2

ONCOL

3.8k ×1.0

PRM

3.3k ×1.2

1.6k ×0.9

IMMUN

Citations per year, relative to Eric B. Haura Eric B. Haura (= 1×) peers Timothy A. Yap

Countries citing papers authored by Eric B. Haura

Since Specialization

Citations

This map shows the geographic impact of Eric B. Haura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric B. Haura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric B. Haura more than expected).

Fields of papers citing papers by Eric B. Haura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric B. Haura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric B. Haura. The network helps show where Eric B. Haura may publish in the future.

Co-authorship network of co-authors of Eric B. Haura

This figure shows the co-authorship network connecting the top 25 collaborators of Eric B. Haura. A scholar is included among the top collaborators of Eric B. Haura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric B. Haura. Eric B. Haura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Saltos, Andreas, Tawee Tanvetyanon, Ben Creelan, et al.. (2023). Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results.. Journal of Clinical Oncology. 41(16_suppl). 9125–9125. 2 indexed citations

Cornelissen, Robin, Arsela Prelaj, Sophie Sun, et al.. (2023). Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4). Journal of Thoracic Oncology. 18(8). 1031–1041. 34 indexed citations

Thapa, Ram, Michael Shafique, Andreas Saltos, et al.. (2023). Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation. Journal of Thoracic Disease. 15(11). 6115–6125. 4 indexed citations

Bertino, Erin M., Ryan D. Gentzler, Jill Kolesar, et al.. (2020). Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clinical Cancer Research. 27(6). 1604–1611. 31 indexed citations

Gray, Jhanelle E., Andreas Saltos, Tawee Tanvetyanon, et al.. (2019). Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research. 25(22). 6623–6632. 104 indexed citations

Smith, Matthew A., Hans‐Ulrich Schildhaus, Vincent Vuaroqueaux, et al.. (2017). MET–GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors. Clinical Cancer Research. 23(22). 7084–7096. 11 indexed citations

Vaishnavi, Aria, Laura Schubert, Uwe Rix, et al.. (2017). EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Research. 77(13). 3551–3563. 61 indexed citations

Woods, Nicholas T., Gabriëla Wright, Lily L. Remsing Rix, et al.. (2016). PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer. Molecular Cancer Therapeutics. 15(7). 1669–1681. 21 indexed citations

Li, Jiannong, Bin Fang, Fumi Kinose, et al.. (2016). Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling. Molecular Cancer Therapeutics. 15(2). 334–342. 18 indexed citations

10.

Zheng, Hong, Weipeng Zhao, Cihui Yan, et al.. (2016). HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. Clinical Cancer Research. 22(16). 4119–4132. 264 indexed citations

11.

Kim, Jae‐Young, Eric A. Welsh, Bin Fang, et al.. (2016). Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS -Mutant Lung Cancer. Molecular Cancer Research. 14(10). 1019–1029. 54 indexed citations

12.

Huang, Qingling, Valentina E. Schneeberger, Noreen Luetteke, et al.. (2016). Preclinical Modeling of KIF5B–RET Fusion Lung Adenocarcinoma. Molecular Cancer Therapeutics. 15(10). 2521–2529. 63 indexed citations

13.

Challa, Sridevi, Xiaowen Ding, Cheng‐Xiong Xu, et al.. (2016). IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non–Small Cell Lung Cancer with Activating Mutations of EGFR. Cancer Research. 76(15). 4418–4429. 30 indexed citations

14.

Pillai, Smitha, José G. Treviño, Bhupendra Rawal, et al.. (2015). β-Arrestin-1 Mediates Nicotine-Induced Metastasis through E2F1 Target Genes That Modulate Epithelial–Mesenchymal Transition. Cancer Research. 75(6). 1009–1020. 73 indexed citations

15.

Yoshida, Takeshi, Guolin Zhang, Matthew A. Smith, et al.. (2014). Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer. Clinical Cancer Research. 20(15). 4059–4074. 89 indexed citations

16.

Gridling, Manuela, Scott B. Ficarro, Florian P. Breitwieser, et al.. (2014). Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics. Molecular Cancer Therapeutics. 13(11). 2751–2762. 20 indexed citations

17.

Bai, Yun, Jae‐Young Kim, Bin Fang, et al.. (2014). Adaptive Responses to Dasatinib-Treated Lung Squamous Cell Cancer Cells Harboring DDR2 Mutations. Cancer Research. 74(24). 7217–7228. 34 indexed citations

18.

Simon, George R., Anupama Sharma, Xueli Li, et al.. (2007). Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 25(19). 2741–2746. 147 indexed citations

19.

Song, Lanxi, Mark Morris, Tapan Bagui, et al.. (2006). Dasatinib (BMS-354825) Selectively Induces Apoptosis in Lung Cancer Cells Dependent on Epidermal Growth Factor Receptor Signaling for Survival. Cancer Research. 66(11). 5542–5548. 183 indexed citations

20.

Dasgupta, Piyali, et al.. (2006). Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proceedings of the National Academy of Sciences. 103(16). 6332–6337. 248 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact